|Page (1) of 1 - 01/05/18||email article||print page|
AxoGen to Participate at AAHS ASPN ASRM 2018 Annual Meetings(January 05, 2018)
ALACHUA, Fla., Jan. 05, 2018 (GLOBE NEWSWIRE) -- AxoGen Corporation (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve damage, today announced its participation at the combined 2018 Meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN), and the American Society for Reconstructive Microsurgery (ASRM). The meeting will take place in Phoenix, Arizona from January 10-16, 2018. This annual combined meeting brings together more than 850 clinicians representing hand and plastic surgeons to learn about emerging clinical evidence and surgical techniques in a peer-to-peer setting.
AxoGen will host an educational symposium on Thursday, January 11, 2018 at 1:00 p.m. “Overcoming Challenges in Nerve Repair: The Recent Evolution of the Evidence-Based Algorithm” will focus on the rapidly growing body of peer-reviewed literature related to peripheral nerve repair. A faculty panel of renowned surgeons will share how they have implemented new techniques and algorithms into their own practices. The interactive symposium will include practical advice, supported by clinical evidence, that can be implemented immediately.
“We are pleased with the increased number and variety of peripheral nerve repair presentations at this scientific meeting and believe their inclusion reflects a growing interest in the clinical evidence supporting our platform for nerve repair,” stated Karen Zaderej, AxoGen’s president and CEO. “It is gratifying to see our ongoing commitment to clinical research and advancing the science of peripheral nerve repair being recognized by these leading professional societies.”
In addition to the company-sponsored symposium, there are several abstracts, posters, and podium presentations related to AxoGen products during the meeting. Bauback Safa, M.D. will present Motor Functional Recovery after Median Nerve Reconstructions using Processed Nerve Allografts on Friday, January 12th during the Scientific Paper presentations. The presentation is based on data from the AxoGen-sponsored RANGER® registry, and includes an updated dataset for these specific mixed and motor nerve injuries.
Also on Friday, Immediate Allograft Outcomes of Long Span Defects of the Inferior Alveolar Nerve, authored by David Salomon, DDS; Michael R Markiewicz, MD, DDS, MPH; and Michael Miloro, MD, DMD, FACS, will include outcomes of long-gap nerve repair in oral and maxillofacial cases.
Avive® Soft Tissue Membrane will be featured in a poster, Peripheral Nerve Surgery with Processed Human Umbilical Cord: Clinical Case Series, authored by Andrew Watt, M.D., Paul Sibley, M.D., Robert Hagan, M.D., Mark S. Rekant, M.D., Harry Hoyen, M.D., and Bauback Safa, M.D.
Two presentations highlighting data from the development of AxoGuard® Nerve Cap are also included in the meeting agenda, Application of a Porcine SIS Nerve Cap for Prevention of Neuromas and Associated Pain and Prevention of Neuromas with a Porcine SIS Nerve Cap: A Histopathological Evaluation. These pre-clinical presentations include data on the reduction of pain and histological findings from the use of AxoGuard® Nerve Cap for the prevention of painful or symptomatic neuroma. The AxoGuard® Nerve Cap, which received FDA clearance last year, may provide surgeons with a new option to protect the peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of a symptomatic or painful neuroma. AxoGen continues to evaluate the application of current and new products in the surgical management of pain.
Additional panel discussions, scientific papers, and posters related to AxoGen products and clinical studies will be presented throughout the conference. Conference attendees can learn more about AxoGen’s platform for nerve repair by visiting Booth #13 in the exhibit hall.
The American Association for Hand Surgery represents a diverse but cohesive mix of highly respected professionals working in all disciplines of hand surgery and hand therapy. Members include orthopedic surgeons, plastic surgeons, general surgeons, microsurgeons, hand therapists, nurses, and basic scientists from the United States, Canada, and many other countries. For more information, please visit: www.handsurgery.org.
The American Society for Peripheral Nerve was established to stimulate and encourage study and research in the field of neural regeneration, to provide a forum for the presentation of the latest research and relevant clinical information and to serve as a unifying authority on all areas of neural regeneration and restorative neuroscience. For more information, please visit: www.peripheralnerve.org.
The American Society for Reconstructive Microsurgery was established to promote, encourage, foster, and advance the art and science of microsurgery and complex reconstruction and to establish a forum for teaching, research and free discussion of reconstructive microsurgical methods and principles. For more information, please visit: www.microsurg.org.
About the RANGER® Study
The RANGER® Study, A Multicenter Retrospective Study of Avance® Nerve Graft Utilization Evaluations and Outcomes in Peripheral Nerve Injury Repair is an active, multicenter clinical database designed to continuously monitor and collect injury, repair, safety, and outcomes data for peripheral nerve injuries repaired with processed nerve allograft (Avance® Nerve Graft), nerve autograft, and synthetic tubes. The study currently includes more than 1,300 nerve repairs enrolled in more than 30 centers. The RANGER® Study is an AxoGen sponsored ongoing open label registry study. Each patient outcome is dependent upon the nature and extent of nerve loss or damage, timing between nerve loss and repair and the natural course of the patient’s recovery.
AxoGen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Damage to a peripheral nerve can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
AxoGen's platform for nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal® Neurosensory & Motor Testing System and AxoTouch® Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "projects," "forecasts," "continue," "may," "should," "will," and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our assessment on our internal control over financial reporting, our growth, our 2017 and 2018 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Peter J. Mariani, Chief Financial Officer
The Trout Group – Investor Relations